AOD-9604: Molecular Characterization and Structural Context — A Research Reference

The parent is human growth hormone, a 191-residue protein of roughly 22 kilodaltons — a folded protein, not a peptide, and two orders of magnitude larger than most of this catalogue. Its architecture was resolved crystallographically in complex with the extracellular domain of its receptor, establishing a four-helix bundle and defining which surfaces of the protein contact the receptor [1]. That structure is the reference frame against which any fragment of the parent is interpreted.

AOD-9604 corresponds to the parent's carboxyl-terminal region, residues 177 through 191, with one addition: a tyrosine placed at the amino terminus of the fragment. That gives a sixteen-residue peptide with a molecular weight of approximately 1,815 daltons.

The fragment inherits two cysteines from the parent — the residues at positions 182 and 189 in the protein's numbering — and in the correctly made peptide they are joined by a disulfide bond. The bridge closes an eight-residue loop within the chain, so the molecule is conformationally constrained in the same spirit as a cyclic peptide, but through a sulphur-sulphur bond rather than a backbone or side-chain amide.

A short fragment excised from a folded protein does not necessarily retain the conformation it held in the parent, and for this region the question has been examined directly. Nuclear magnetic resonance study of the C-terminal fragment of human growth hormone characterized its solution behaviour in isolation, addressing what structure — if any — the excised sequence adopts once removed from the surrounding helical bundle [2].

That is the substantive structural question for any fragment product, and it is worth separating from the question of identity. A batch can be the correct sequence with the correct disulfide and still be conformationally unlike the corresponding region of the intact protein, because the parent's fold is maintained by contacts the fragment no longer has. The disulfide bridge is the one structural constraint that survives excision, which is part of why its presence is worth verifying rather than assuming.

The fragment-versus-parent distinction is otherwise straightforward: a 1.8-kilodalton peptide and a 22-kilodalton protein share a name lineage but are unambiguously separated by mass, and the certificate's stated theoretical figure identifies which entity a batch is.

Mass spectrometry confirms the intact molecular mass, and for a disulfide-bridged peptide the measurement reads on the bridge itself. Forming the bond releases two hydrogens, so the bridged peptide is two daltons lighter than its fully reduced counterpart — a small but defined difference that adequate resolving power detects. An observed mass matching the reduced form indicates the bridge never formed.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. Beyond the deletion sequences familiar to any sixteen-residue synthesis, the compound-specific related substances are the disulfide variants: the reduced open-chain form, and dimers where the bridge formed between two chains rather than within one. Interchain pairing is the characteristic failure mode of cysteine-containing peptides and is chromatographically visible — dimers elute apart from the monomer and carry exactly twice its mass, so the two methods corroborate one another on this point.

Net peptide content accounts for counter-ions and residual water, determining how much peptide a nominal milligram figure represents.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

One consideration is specific to disulfide-bridged peptides. Reducing agents cleave the bridge, so glassware or media carrying residues of dithiothreitol or similar reagents from earlier procedures will quietly convert the constrained peptide into its open-chain form — an interference invisible until the material is analysed again. Dedicated or thoroughly rinsed labware avoids it.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze-thaw cycling is avoided.

The bridge adds one further storage behaviour: disulfides exchange under alkaline conditions, where free thiols catalyse reshuffling between and within chains. Solutions of this compound are therefore not held at high pH, and the robust-looking loop should not be mistaken for general chemical inertness.

AOD-9604 is an investigational compound. It has not been approved by the FDA or any other regulatory authority, and no manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade AOD-9604 is accompanied by an independent certificate of analysis specific to that lot.

AOD-9604 is a sixteen-residue peptide of approximately 1,815 daltons: the carboxyl-terminal 177–191 region of human growth hormone with an added N-terminal tyrosine, closed by an internal disulfide bridge between the two inherited cysteines. The parent protein's architecture is known crystallographically, and the isolated C-terminal fragment's solution behaviour has been examined by nuclear magnetic resonance — a distinction worth holding, since a correct sequence with a correct disulfide need not reproduce the conformation the region held within the intact fold. Analytical verification rests on mass confirmation of the closed bridge, chromatographic resolution of reduced and dimeric forms, and batch-specific net peptide content.